Canton Strategic Holdings, Inc. CNTN

Canton Strategic Holdings, Inc. (CNTN) announced the sale of Gravitas Life Sciences, LLC. Sale of subsidiary represents strategic divestiture likely to produce moderate effects on operations and valuation.

Tharimmune, Inc. (THAR) has announced a registered direct public offering of common stock and warrants, priced at $1.74 million. The offering aims to raise funds to support the company's ongoing operations and development initiatives. The securities will be offered to a select group of institutional investors, with the closing of the transaction expected to occur shortly. The capital raised through this offering may enhance Tharimmune's financial position and support its operational initiatives.

Canton Strategic Holdings, Inc. (CNTN) advances Canton Network growth and DTCC pilot momentum per Tharimmune investor update. Canton Network expansion and DTCC pilot advancements support improved strategic positioning for CNTN.

Canton Strategic Holdings, Inc. (CNTN) launches Locking Service to support network infrastructure providers. New service launch may expand CNTN operations and attract infrastructure clients.

Tharimmune highlighted Canton Network's Q1 growth, tokenomics shift, and validator locking in a webinar. Q1 growth, tokenomics shift, and validator locking represent major strategic enhancements boosting network adoption and investor confidence.

Tharimmune, Inc. has appointed Mark Wendland as Chairman of the Board and Angela Radkowski as Chief Operating Officer. These leadership changes are expected to enhance the company's strategic direction and operational efficiency. Leadership changes can moderately influence the company's operational effectiveness and strategic initiatives.

Tharimmune, Inc. has appointed Jill Sommers and William Wiley to its Board of Directors. Sommers brings extensive experience in regulatory affairs and compliance, while Wiley has a strong background in finance and corporate governance. Their appointments are expected to enhance the company's strategic direction and oversight. The addition of experienced board members may positively influence Tharimmune's strategic decisions and governance.

Tharimmune, Inc. shareholders have approved the election of directors, warrant-linked share issuances, and a plan to increase the number of shares by 7 million. These approvals are expected to enhance the company's financial flexibility and support its strategic initiatives. The approved measures may moderately influence Tharimmune's financial performance and operational strategy.

Tharimmune, Inc. has successfully closed a $55 million underwritten registered direct offering. The offering was conducted with institutional investors, and the proceeds are intended to be used for general corporate purposes, including advancing the company's pipeline and operational needs. The transaction is expected to enhance Tharimmune's financial position and support its strategic initiatives. The $55 million funding is a significant boost that can enhance operational capabilities and support strategic initiatives.

Tharimmune, Inc. has announced the pricing of a $55 million underwritten registered offering. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The shares will be offered at a set price, with the company planning to use the proceeds for general corporate purposes, including research and development. The offering is likely to provide necessary funding for development, impacting financial performance moderately.

Tharimmune, Inc. (THAR) experienced a 30% stock increase following a successful $540 million capital raise aimed at developing its Canton Coin Treasury Strategy. This significant funding is expected to bolster the company's financial position and support its strategic initiatives in the cryptocurrency space. The capital raise represents a major strategic move that could significantly alter the company's trajectory and investor sentiment.

Tharimmune, Inc. (THAR) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect broader market trends or specific developments related to the company's operations or strategic initiatives. Investors are closely monitoring THAR's performance as it could signal potential opportunities or risks in the near future. Increased trading activity suggests a moderate influence on market sentiment and potential interest in the company's future performance.

Insider buying activity at Tharimmune, Inc. (THAR) has been noted, with several executives purchasing shares of the company. This trend is often seen as a positive indicator of confidence in the company's future prospects. The increased insider ownership may signal to investors that those with the most knowledge of the company believe in its potential growth and stability. Insider buying can indicate confidence in the company's future, potentially influencing market sentiment and stock performance.

Tharimmune, Inc. announced upcoming conference presentations that will highlight its lead asset, TH104, a new formulation designed to combat ultrapotent opioids and fentanyl. The presentations aim to showcase the potential of TH104 in addressing the opioid crisis and its innovative approach to treatment. The introduction of TH104 could significantly impact Tharimmune's market position and investor sentiment in the context of the ongoing opioid crisis.

Tharimmune, Inc. (THAR) experienced a significant decline of 20.7% in its stock price following the announcement of a $5 million share sale. The move raised concerns among investors about potential dilution of shares and the company's financial health. Market analysts are closely monitoring the situation as the sale could impact investor sentiment and future funding strategies. The share sale may affect investor confidence and financial performance but is not expected to fundamentally alter the company's trajectory.

Tharimmune, Inc. (THAR) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect recent developments or market sentiment surrounding the company, potentially influencing its stock performance and future operations. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Tharimmune, Inc. (THAR) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect investor sentiment or reactions to recent developments related to the company or its sector. The increased trading volume could influence the stock's price movements and overall market perception. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Tharimmune, Inc. (THAR) announced promising pharmacokinetic simulation results for its drug TH104, designed to prevent respiratory depression caused by fentanyl and other ultrapotent opioids. The results suggest that TH104 may offer superior efficacy compared to existing treatments, potentially addressing a critical need in opioid overdose management. This development could position Tharimmune favorably in the market as it seeks to enhance patient safety and treatment options in the face of the opioid crisis. The simulation results indicate a significant advancement in opioid overdose treatment, which could greatly enhance Tharimmune's market position and investor interest.

Tharimmune, Inc. (THAR) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect investor sentiment or reactions to recent developments related to the company. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential interest in the company's future performance.

Tharimmune, Inc. has secured key global patents for its drug TH-104, which is initially developed as a national security medical countermeasure against weaponized fentanyl. This patent acquisition lays the groundwork for expanding TH-104's indications beyond its initial purpose, potentially enhancing its marketability and applications in various medical fields. Securing global patents for TH-104 could significantly enhance Tharimmune's strategic position and market opportunities.

Nancy Davis, a prominent philanthropist known for founding Race to Erase MS and Cure Addiction Now, has been appointed to the Board of Directors of Tharimmune, Inc. (THAR). Her extensive experience in advocacy and fundraising for health-related causes is expected to enhance the company's strategic direction and community engagement efforts. Davis's appointment may positively influence Tharimmune's strategic initiatives and public perception, but the overall impact on the company's trajectory is expected to be limited.

Tharimmune, Inc. (THAR) has issued a comprehensive corporate update highlighting its lead product, TH104, as a critical national security solution against weaponized fentanyl. Additionally, the company is advancing TH023, which aims to revolutionize oral antibody delivery. These developments position Tharimmune as a key player in addressing significant health threats and enhancing drug delivery methods. The introduction of TH104 as a solution against weaponized fentanyl and the potential of TH023 to transform oral antibody delivery represent significant strategic advancements for the company.

Tharimmune, Inc. (NASDAQ:THAR) announced key leadership changes, appointing Sireesh Appajosyula as CEO and Vincent LoPriore as Executive Chairman. The company also welcomed James Gordon Liddy to its Board of Directors. Tharimmune is advancing its lead candidate, TH104, designed for rapid delivery of an opioid antagonist to counteract high-potency opioids like weaponized fentanyl. Appajosyula, previously COO, aims to drive innovation in therapeutic candidates, while Liddy brings expertise in national security, crucial for TH104's development. Tharimmune continues to focus on unmet medical needs in immunology and inflammation. Leadership appointments and the advancement of TH104 represent significant strategic moves that could enhance the company's market position and investor sentiment.

Tharimmune, Inc. has appointed James Gordon Liddy, a former Navy SEAL and counter-terrorism expert, as a strategic advisor to aid in the development of TH104, a prophylactic treatment against high-potency opioids like fentanyl. Liddy brings extensive experience in national security and counter-terrorism, which will help guide Tharimmune's strategy as it seeks FDA approval for TH104. The FDA has provided positive feedback, indicating no additional clinical trials are needed before submitting a New Drug Application. Tharimmune aims to address the urgent need for effective countermeasures for military personnel and first responders exposed to these dangerous substances. The appointment of a high-profile advisor and positive FDA feedback significantly enhances Tharimmune's strategic positioning and potential market impact.

Tharimmune, Inc. presented positive pharmacokinetic data from its Phase 1 study of TH104, a buccal film formulation of nalmefene, at Digestive Disease Week 2025. The study demonstrated that TH104 provides a distinct metabolic profile compared to intravenous nalmefene, with slower absorption and delayed phase 1 metabolism, potentially benefiting individuals with impaired liver function. Following favorable feedback from the FDA, Tharimmune is advancing TH104 for prophylaxis against opioid exposure in military personnel and chemical incident responders, pursuing a 505(b)(2) regulatory pathway without the need for additional clinical trials. The results also indicated comparable safety and tolerability between TH104 and IV nalmefene, with only mild adverse events reported. The FDA's positive feedback and the advancement of TH104 for a critical prophylactic indication represent a significant strategic move for Tharimmune.

Tharimmune, Inc. announced that its abstracts have been accepted for presentation at the upcoming Digestive Disease Week (DDW) and European Association for the Study of the Liver (EASL) conferences. These presentations are expected to showcase the company's advancements in immunotherapy and its potential applications in treating liver diseases, highlighting Tharimmune's commitment to innovation in the field. Presentations at major conferences can significantly enhance visibility and credibility, potentially attracting investors and partners.

Tharimmune, Inc. announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, expanding the Board to nine members. Following the decision of Directors Leonard Mazur and Lynne Bui, M.D. not to seek re-election, the Board will reduce to seven members after the 2025 Annual Meeting on June 10. Kahler and Stetz bring extensive experience in life sciences, finance, and corporate governance, with Kahler serving on the audit and compensation committees and Stetz on the compensation and audit committees. Their appointments aim to enhance Tharimmune's strategic growth and governance as the company advances its clinical programs and product pipeline. The appointments of experienced directors are likely to significantly impact Tharimmune's strategic direction and governance.

Tharimmune, Inc. has received positive feedback from the FDA regarding its drug TH104, which is being developed for the prophylaxis against weaponized fentanyl and other high-potency opioids. This advancement positions Tharimmune to address critical public health concerns related to opioid overdoses and could enhance its market presence in the pharmaceutical sector focused on opioid-related treatments. Positive FDA feedback on TH104 indicates a significant step towards addressing a pressing health crisis, likely impacting Tharimmune's strategic positioning and market performance.

Tharimmune, Inc. has appointed Vincent LoPriore to its Board of Directors, enhancing its strategic leadership. LoPriore brings extensive experience in the biotechnology sector, having held various leadership roles in prominent companies. His expertise is expected to contribute significantly to Tharimmune's growth and strategic direction. The appointment of a seasoned leader may positively influence Tharimmune's strategic initiatives and market positioning.

Tharimmune, Inc. announced positive data regarding its novel biparatopic PD-1/VEGF and multispecific HER2/HER3 biologics, which utilize the proprietary EpiClick(TM) technology. These advancements suggest potential improvements in cancer treatment efficacy, positioning Tharimmune favorably in the competitive biopharmaceutical landscape. The introduction of innovative biologics leveraging proprietary technology is likely to significantly impact Tharimmune's market position and investor sentiment.